Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deferred Tax Liability (2016 - 2018)

Niagen Bioscience (NAGE) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $218000.0 as the latest value for Q4 2019.

  • On a quarterly basis, Non-Current Deferred Tax Liability rose 1047.37% to $218000.0 in Q4 2019 year-over-year; TTM through Dec 2019 was $218000.0, a 1047.37% increase, with the full-year FY2019 number at $218000.0, up 1047.37% from a year prior.
  • Non-Current Deferred Tax Liability was $218000.0 for Q4 2019 at Niagen Bioscience, up from $19000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $413000.0 in Q1 2016 to a low of $19000.0 in Q4 2018.
  • A 3-year average of $262250.0 and a median of $308500.0 in 2016 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: fell 3.39% in 2016, then skyrocketed 1047.37% in 2019.
  • Niagen Bioscience's Non-Current Deferred Tax Liability stood at $399000.0 in 2016, then plummeted by 95.24% to $19000.0 in 2018, then surged by 1047.37% to $218000.0 in 2019.
  • Per Business Quant, the three most recent readings for NAGE's Non-Current Deferred Tax Liability are $218000.0 (Q4 2019), $19000.0 (Q4 2018), and $399000.0 (Q4 2016).